Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
5.58 USD -0.36% Intraday chart for Puma Biotechnology, Inc. +18.85% +28.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise MT
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer CI
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Puma Biotechnology, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37 MT
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer CI
Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer CI
Transcript : Puma Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q3 EPS $0.17, vs. Street Est of $0.14 MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023 CI
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting CI
North American Morning Briefing : Stock Futures Edge Higher as PMI Data Awaited DJ
Puma Biotechnology Gets FDA Orphan Drug Designation For Alisertib MT
Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation DJ
Puma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer Drug DJ
FDA Clears Puma Biotechnology to Begin Mid-Stage Trial in Small Cell Lung Cancer MT
Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer CI
Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Puma Biotechnology, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q2 EPS $0.10, vs. Street Est of $0.07 MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023 CI
Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting CI
Chart Puma Biotechnology, Inc.
More charts
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
5.58 USD
Average target price
4.333 USD
Spread / Average Target
-22.34%
Consensus
  1. Stock
  2. Equities
  3. Stock Puma Biotechnology, Inc. - Nasdaq
  4. News Puma Biotechnology, Inc.
  5. Puma Biotechnology : Expands Common Share Issuance Under Incentive Stock Options by 2 Million